Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603439's Forward Dividend Yield % is ranked worse than 81.64% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.005
vs SHSE:603439: 0.52
During the past 12 months, Guizhounli Pharmaceutical Co's average Dividends Per Share Growth Rate was 70.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Guizhounli Pharmaceutical Co was -7.20% per year. The lowest was -7.20% per year. And the median was -7.20% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Guizhounli Pharmaceutical Co (SHSE:603439) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Guizhounli Pharmaceutical Co Forward Dividend Yield % Related Terms
SHSE:603439 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Guizhounli Pharmaceutical Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guizhounli Pharmaceutical Co Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guizhounli Pharmaceutical Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Guizhounli Pharmaceutical Co's Forward Dividend Yield % falls into.
Guizhounli Pharmaceutical Co Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Guizhounli Pharmaceutical Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
CNY 0.060000
2026-06-30
2026-06-29
2026-06-30
Cash Dividend
annually
CNY:CNY 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 0.52% mean?
Guizhounli Pharmaceutical Co (SHSE:603439) has a Forward Dividend Yield % of 0.52% as of Jul. 16, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Guizhounli Pharmaceutical Co and its competitors. According to the industry distribution chart, Guizhounli Pharmaceutical Co ranks #418 out of 512 companies in the Drug Manufacturers industry, placing it in the top 81.6%.
Is Guizhounli Pharmaceutical Co's Forward Dividend Yield % too high?
Guizhounli Pharmaceutical Co's current Forward Dividend Yield % is 0.52%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.01. Guizhounli Pharmaceutical Co's value of 0.52% is 74.1% below this industry median. Based on the distribution chart, Guizhounli Pharmaceutical Co ranks #418 out of 512 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guizhounli Pharmaceutical Co ranks #418 out of 512 companies for Forward Dividend Yield %. This places Guizhounli Pharmaceutical Co in the lower half of its industry. The industry median Forward Dividend Yield % is 2.01. Guizhounli Pharmaceutical Co's value of 0.52% is 74.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.01, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current Forward Dividend Yield % of 0.52% is 74.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Guizhounli Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current Forward Dividend Yield % is 0.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.70, compared to a current price of ¥11.41 — trading 22.4% below its estimated fair value. The current Forward Dividend Yield % is 0.52% and 74.1% below the Drug Manufacturers industry median of 2.01. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current Forward Dividend Yield % is 0.52% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥11.41 is trading 22.4% below its estimated GF Value™ of ¥14.70.
GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603439:
Forward Dividend Yield %: 0.52%
GF Value™: ¥14.70 vs. price of ¥11.41 (22.4% below fair value)
Industry Position: 74.1% below the Drug Manufacturers median (#418 of 512)
No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score
Get the complete analysis for SHSE:603439
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603439 has been successfully added to your 
